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ABSTRACT
Circulating miRNAs are protected from ribonuclease degradation by assembly into
microvesicles and exosomes. Releasing miRNAs completely from these particles is the
key step to quantify the circulating miRNAs. Currently purified RNA-based quantitative
analysis is widely used while it is time and cost consuming with high risk for those
circulating miRNAs with low abundance due to partial loss of RNA during the steps
of total RNA extraction and small RNA enrichment. Herein, we optimized a simple,
effective and time-saving method to directly measure plasma miRNAs without RNA
isolation. It is based on complete miRNA release from the protein complexes, followed
by miRNA-specific reverse transcription and quantitative real-time PCR amplification.
By comparison to the RNA-based approach, the direct quantification method showed
more efficiency for circulating miRNA analysis, higher accuracy and specificity. By
application of the direct quantification method to clinical samples combined with
the RNA-based miRNA screening analysis, upregulation of miR-106a in blood was
validated in metastatic breast cancer patients, indicating miR-106a are a potential
biomarker for metastatic breast cancer.

INTRODUCTION

translational efficiency of targeted messenger RNAs.
Mature miRNAs have length ranging from 18 to 24 nt.
More than 2,000 miRNA sequences have been identified
or predicted from human-origin cells. miRNAs can be
assembled into ribonucleic protein complexes known as
RNA-induced silencing complex (RISC) that lead to basepairing interactions between a miRNA and the binding
site of its target mRNAs mostly within the 3′ untranslated
region (3′UTR). miRNAs regulate diverse biological
processes including cell fate determination, cell cycle
progression, stem cell self-renewal, cancer initiation,
cancer cell proliferation and cancer cell metastasis [2–8].
miRNAs are present in body fluids including
blood, plasma, serum, saliva, urine and milk [9–12]. The

The Human Genome Project has demonstrated that
more than 93% of the genome DNA can be transcribed to
RNA while less than 2% of transcripts encode functional
proteins [1], indicating most of the transcripts are
non-coding RNAs (ncRNA). Those ncRNAs with length
< 200 nt are called small non-coding RNAs and include
transfer RNA (tRNA), ribosomal RNA (rRNA), small
nuclear RNA (snoRNA), microRNA (miRNA), small
interference RNA (siRNA) and piwi-interacting RNA
(piRNA).
miRNAs are a class of multifunctional singledstranded small molecules that regulate the stability or
www.impactjournals.com/oncotarget
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extracellular miRNAs circulating in the blood of both
healthy and diseased people, are referred to circulating
miRNAs. Most of the circulating miRNAs are protected
from ribonuclease degradation by cofractionating with
proteins or assembling in lipid or lipoprotein complexes,
such as microvesicles and/or exosomes [13, 14]. Therefore,
circulating miRNAs are highly stable in blood. Although
the understanding of how miRNAs are selectively released
from cells and how the circulating miRNAs are related to
disease remains largely unclear, circulating miRNAs may
serve as novel diagnostic and prognostic biomarkers for
human diseases including cancer [15]. Emerging evidence
suggests secreted miRNAs function as heterotypic
signals to regulate the breast cancer phenotype [16] and
circulating miRNAs may serve as heterotypic signaling
molecules for intercellular communication by functioning
in recipient cells [17].
Breast cancer is the most common nondermatological cancer in women. Although the 5-year
survival has reached around 98% in localized breast
cancer [18], metastatic breast cancer, which occurs in
20%–30% of breast cancer patients, remains incurable
partly due to the lack of a reliable biomarker for early
diagnosis before metastasis occurs [19]. miRNAs regulate
breast cancer initiation and progression functioning as
either tumor suppressors or oncogenes [6, 20]. Altered
expression of miRNAs or mutation of miRNA genes
have been described in human breast cancer. As early as
in 2005, Lorio et al identified 29 miRNAs with aberrant
expression in human breast cancer by analysis on 76 breast
tumor samples and 14 human breast cell lines [21]. Zhang
and his colleagues analyzed 283 human miRNA genes in
55 human breast primary tumors and 18 human breast
cancer cell lines, demonstrating a high frequency (~72.8%)
of gene copy number abnormality in miRNA-containing
regions in human breast cancer [22]. A growing body of
evidence implicates miRNAs in regulating breast cancer
metastasis as well as epithelial to mesenchymal transition
(EMT).
Although the function of circulating miRNAs in
breast cancer is not well understood, emerging evidence
suggests circulating miRNA may be important in
diagnosis and prognosis of breast cancer. Circulating
miRNA in blood of breast cancer patients demonstrate
increased levels of miR-195 and let-7a compared to
control subjects [23]. A recent report proposed miR-181
a-5p as a diagnostic breast cancer biomarker because
of a significant reduction of circulating miR-181a-5p
level in breast cancer patients’ serum [24]. However, the
circulating miRNAs in metastatic breast cancer remains
to be determined.
Currently methods for circulating miRNA analysis
are mainly based on RNA purification and small RNA
enrichment. It is unavoidable to have part of the circulating
miRNAs lost due to the incomplete denaturation of protein
and/or incomplete precipitation of RNA, which may lead
www.impactjournals.com/oncotarget

to failure to detect low abundance miRNAs. Yoon et al
reported an assay to detect mRNA and miRNA directly
from cell lysates (cell to Ct) without RNA isolation
[25]. Sota et al reported a direct serum assay for miRNA
analysis in cancer patient [26]. Both reports lacked
evaluation of the specificity, accuracy and efficiency
of the direct approach, which limits the reliability and
applicability. In the present study we optimized a simple,
effective and time-saving method to directly measure the
plasma miRNA without RNA purification. The method is
based on a complete denaturation of miRNA-containing
microvesicles and/or exosomes, miRNA release from
those complexes, followed by miRNA-specific reverse
transcription and quantitative real-time PCR amplification
(QRT-PCR). RNA isolation and purification is not required
in this assay. It greatly shortens the time and decreases the
cost for the circulating miRNAs measurement compared
to the traditional RNA-based assays. More importantly,
the direct quantification method showed more efficiency
for measuring circulating miRNAs compared to the RNAbased approaches. By applying the direct quantification
method, we validated changes in circulating miR-106a
levels in metastatic breast cancer, and proved evidence
for the potential as a biomarker specifically for metastatic
human breast cancer.

RESULTS
Direct quantification of circulating miRNAs
from plasma without RNA purification
In order to determine how circulating miRNAs can
be released efficiently from microvesicles and exosomes
in blood and whether the released miRNAs can be directly
amplified for quantitative analysis, different methods for
denaturing protein, including chemical detergents and
heating treatment, were compared. As shown in Figure 1A,
aliquots of 5 µl plasma were treated by M1 (75°C for 5 min
alone), M2 (treated with same volume of denaturing buffer
containing Tween20, Tris and EDTA) or M3 (denaturing
buffer reaction followed by heat treatment), respectively.
The released circulating miRNAs were immediately
reverse-transcribed to cDNA without further RNA
purification. Using the cDNA as template, two of the most
abundant small RNAs in plasma, 5s rRNA and miR-16,
were amplified by QRT-PCR reaction (Figure 1B and 1C).
For both 5s rRNA (Figure 1B) and miR-16 (Figure 1C),
M3 showed the highest efficiency for gene amplification,
M1 showed less efficiency (M1 vs M3, ∆Ct ~1 cycle)
while M2 showed the lowest efficiency (M2 vs M3,
∆Ct ~10 cycles). The results demonstrated the feasibility
of circulating miRNAs direct amplification using plasma
without RNA purification, and indicated that approach
M3 has the highest efficiency to release miRNAs from
protein complexes for further analysis. SDS, which is used
the most frequently for protein denaturation, was tested
21866

Oncotarget

to release circulating miRNAs from protein complexes,
followed by a miRNA direct quantification analysis. As
shown in Supplementary Figure S1, none of the three
tested small RNAs were amplified after SDS treatment,
indicating the existence of SDS in the reaction system may
have severe inhibition to miRNA amplification.

respectively (Figure 2A and 2B). The Log2 ∆Ct had a
perfect correlation with the plasma volume (Figure 2C)
indicating the miRNA quantification result reflects the real
abundance of miR-16 in the reaction system.
In addition, direct quantification of circulating
miRNAs was performed in multiple plasma samples with
different dilutions of cDNA to validate the accuracy of the
method. Three plasma samples from randomly selected
three donors were tested for miR-16. cDNAs from
plasma specimens S1, S2 and S3 were diluted by 1:10
and 1:100, respectively (Figure 2D). Circulating miR-16
was analyzed in all diluted cDNAs. The results showed
~3.3 ∆Ct between 1:10 and 1:100 diluted cDNAs in all
the three tested samples (Figure 2D and 2E), representing
the average fold change 10.27 ± 0.61 of the miR-16
abundance in 1:10 compared with 1:100 diluted cDNAs
(Figure 2F). In addition to miR-16, miR-92a and let-7b

The accuracy of the plasma-based direct
quantification of circulating miRNAs
In order to evaluate the accuracy of the plasmabased method for circulating miRNA analysis, different
volumes of plasma (1 µl, 4 µl, and 8 µl) from the same
donor were treated in parallel using method M3, followed
by reverse transcription and QRT-PCR amplification of
miR-16 (Figure 2A–2C). 1 µl, 4 µl, and 8 µl of the plasma
yielded Ct values around 31.8, 29.6 and 28.5 cycles,

Figure 1: Direct quantification of circulating miRNAs using plasma. (A) Schematic representation of the three methods
(M1, M2 and M3) directly analyzing circulating miRNAs from plasma. (B) QRT-PCR analysis of small RNA 5s rRNA from aliquots of
same plasma sample using methods M1, M2 and M3, respectively. (C) QRT-PCR analysis of miR-16 from aliquots of same plasma sample
using methods M1, M2 and M3, respectively.
www.impactjournals.com/oncotarget
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were also measured in S1 cDNA diluted by 1:10 and
1:100. Similar to miR-16, both miR-92a (Supplementary
Figure S2) and let-7b (Supplementary Figure S3) showed
∆Ct around 3.3–3.5 cycles which is consistent with the
10-fold difference in cDNA concentration.

a PCR amplification. Accordingly, the results showed
Ct values 20.8 ± 0.14 and 24.4 ± 0.15 corresponding to
the two diluted cDNAs (Figure 3A), while the control
RNA (without adding unisp6) only had a background
signal. Data analysis indicated the fold change of unisp6
abundance is consistent with the cDNA concentration
(Figure 3B). Similarly, 2 µl of unisp6 was added directly
to a plasma sample for a small RNA quantitative analysis
using the method M3. Unisp6 was undetectable in control
sample, while it had Ct values of 26.44 ± 0.12 and
29.83 ± 0.14 in 1:10 and 1:100 diluted cDNAs,
respectively (Figure 3C). The ~ 10-fold change of unisp6
abundance is consistent with the cDNA concentration
(Figure 3D).
In addition, different amount of unisp6 (0, 1, and
4 µl) were added into aliquots of plasma samples, followed
by protein denaturation, reverse transcription and PCR
amplification. As expected, unisp6 was undetectable in

The specificity of the plasma-based direct
quantification of circulating miRNAs
In order to determine the specificity of the direct
quantification method for circulating miRNA analysis, an
exogenous small RNA named unisp6 was added into either
purified RNA or the original plasma for further analysis.
Firstly it was tested in the RNA sample to ensure the
exogenous RNA is able to be amplified well. 2 µl of unisp6
(1 µl equals to 108 copies) was added to a RNA sample
followed by a miRNA reverse transcription reaction.
The cDNA was diluted with 1:10 and 1:100 followed by

Figure 2: High accuracy of the plasma-based direct quantification of circulating miRNAs. (A) Quantitative analysis of

miR-16 from 1, 4 and 8 µl of plasma sample using methods M3. (B) Ct values in A analysis. (C) The miR-16 abundance showed a linear
positive correlation with the plasma volume with R2 = 0.999. (D) Quantitative analysis of miR-16 from three different plasma samples
(S1, S2 and S3) with 1:10 and 1:100 cDNA dilutions. (E) Actual Ct values and fold changes of miR-16 abundance in the three samples at
cDNA dilution 1:10 vs 1:100. (F) miR-16 abundance showed 10.27 times more in 1:10 than 1:100 diluted cDNAs, which is consistent with
cDNA concentration.
www.impactjournals.com/oncotarget
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the reaction with 0 µl unisp6. The expression levels of
unisp6 correlated with the amount of unisp6 added into the
plasma (Figure 3E). As a form of control, the abundance
of two endogenous small RNAs, miR-16 and 5s rRNA,
did not show change between these samples (Figure 3F
and 3G). Another set of experiments with 0, 2 and 4 µl of
unisp6 added into a plasma sample further confirmed the
specificity and accuracy of this direct quantitative method
for circulating miRNA analysis (Supplementary Figure S4,
S5 and S6).
The results also reflected the sensitivity of the method.
As indicated in Supplementary Figure S5, 2 µl of unisp6,
which equals 2 × 108 copies, gave a Ct value about 28 cycles
for unisp6 amplification. Since Ct values of over 35 cycles
are considered as undetectable level, a minimum of ~106
copies of unisp6 in plasma will be having a maximum Ct of
35 cycles by calculation. As such, 106 copies of miRNA can

be considered as sensitivity limit for the method. In order to
confirm this sensitivity limit, additional experiments were
performed by adding 0 µl, 0.25 µl, 1.0 µl of exogenous
unisp6 into same volume of plasma, followed by a direct
quantification of unnisp6 and 5s rRNA. As shown in
Supplementary Figure S7, Ct values of 30 cycles and
28 cycles corresponded to 0.25 µl and 1.0 µl of unisp6,
respectively. It is consistent with other data demonstrating
the sensitivity limit of 106 copies of miRNAs.

The efficiency of the plasma-based direct
quantification of circulating miRNAs
In order to determine the efficiency of the plasmabased method for measuring circulating miRNAs,
selected plasma samples were either treated with
Trizol to isolate RNA or treated following the M3

Figure 3: High specificity of the plasma-based direct quantification of circulating miRNAs. (A) QRT-PCR analysis of an

exogenous small RNA unisp6 which was added into purified RNA with 1:10 and 1:100 dilutions to cDNA. (B) Quantitative analysis of
unisp6 abundance in A. (C) QRT-PCR analysis of exogenous small RNA unisp6 which was added into plasma with 1:10 and 1:100 dilutions
to cDNA. (D) Quantitative analysis of unisp6 abundance in C. (E) Quantitative analysis of exogenous small RNA unisp6 which was added
into plasma with volume 0, 1 and 4 µl. (F) Quantitative analysis of miR-16 in all cDNAs of E. (G) Quantitative analysis of 5s rRNA in all
cDNAs of E.
www.impactjournals.com/oncotarget
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protocol to release miRNA from protein complexes.
The RNA-based and plasma-based methods were
compared for circulating miRNA analysis in three
randomly selected plasma samples as shown in
Figure 4A–4D. For each sample, identical amounts of
cDNA either derived from purified RNA or derived
directly from plasma were used to measure let-7b and
miR-92a, two circulating miRNAs related to cancer. In both
sample S2 and S3, the plasma-based direct quantification
method showed smaller Ct values, ~0.7–1.1 cycles of
∆Ct compared to the RNA-based method (Figure 4C
and 4D). It is indicative of a higher efficiency of the
plasma-based direct quantification method for circulating
miRNA analysis.
In addition, the expression of circulating let-7b and
miR-92a was analyzed in two randomly selected plasma
samples (S4 and S5) and compared using either the RNAbased method or the plasma-based direct quantification
method (Figure 4E and 4F). Both methods indicated
higher levels of let-7b and miR-92a in S4 than that in S5
(Figure 4G). Furthermore, for both let-7b and miR-92a,
∆∆Ct value between the two methods showed a linear
correlation with R2 equals 1.0 (Figure 4H and 4I),
demonstrating the high accuracy of the plasma-based
direct quantification of circulating miRNA.
The stability of circulating miRNAs and the
reproducibility of the plasma-based direct quantification
method were also tested using plasma samples stored
at a −80°C stored at day 1 and day 5 to measure the
abundance of miR-16 (Supplementary Figure S8) and
let-7b (Supplementary Figure S9). The Ct value showed
strong stability for both miRNA at day 1 and day
5, indicating the stability of circulating miRNAs and
the reproducibility of the direct quantitation method for
miRNA analysis.

(miR-671, miR-151-3p, miR-433 and miR-409-3p) in
breast cancer (Figure 5A). In order to further validate the
results, the plasma-based direct quantification method
was applied to measure the abundance of these miRNAs
in an additional three LN+, three LN− and three normal
control plasma samples. The upregulation of miR-106a
was confirmed in plasma samples from metastatic breast
cancer patients (Figure 5B), which is consistent with the
circulating miRNA screening results (Figure 5A). Notably,
upregulation trend of circulating miR-20b (Supplementary
Figure S10) and downregulation trend of circulating
miR-671 were observed in the metastatic breast cancer
patients. Circulating miR-409-3p showed downregulation
trend in both LN+ and LN− breast cancer patients
(Supplementary Figure S11). However p value did not
show significance change due to the small number of
samples. Still these results provided a subset of candidate
circulating miRNAs as potential biomarkers for metastatic
breast cancer.
In order to further confirm the upregulation of
circulating miR-106a in metastatic breast cancer patients,
additional plasma samples from 10 metastatic breast
cancer patients and 10 control females were collected to
test and compare the levels of circulating miR-106a. As
shown in Supplementary Figure S12, the upregulation of
circulating miR-106a in metastatic breast cancer patients
was confirmed. Although the upregulation of circulating
miR-20b and downregulation of Circulating miR-671
showed the trend in the metastatic breast cancer, it still
needs further validation by analysis on an enlarged set of
samples.

DISCUSSION
Although nucleic acids was first demonstrated
in human blood in 1948 [27], the source, structure and
function of the nucleic acids and their relationship to
human diseases was not exploited until early this century
[28, 29]. The nucleic acids in plasma and serum include
DNA, mRNA, miRNA and lncRNA. The nucleic acids
may be released from blood cells, necrosed cell and
tissues, apoptotic cells, exosomes and DNA/RNAlipoprotein complexes [30]. Changes in the levels of
circulating nucleic acids have been associated with
pathological conditions including cancer progression.
Circulating nucleic acids have been demonstrated to have
potential roles in personalized disease diagnosis, prognosis
and monitoring of therapeutic efficacy. In addition, nucleic
acids in blood may also enter cells and exhibit a biological
activity in the recipient cells [17].
Most of the circulating nucleic acids are protected
from ribonuclease degradation by association with
proteins, lipids or lipoprotein complexes, such as
microvesicles and/or exosomes. Microvesicles, also named
microparticles, are derived from plasma membranes with
size ranging from 100 nm to 1000 nm. Exosomes are cell-

Identification of circulating miRNAs as novel
biomarkers for detecting metastatic breast
cancer
Emerging evidence has demonstrated the potential
of circulating miRNAs as biomarkers for early detection of
cancer. We applied the plasma-based direct quantification
method combined with the RNA-based method to validate
a circulating miRNA signature in metastatic breast cancer.
Total RNA was isolated from six plasma specimens
of breast cancer patients including three lymph node
positive (LN+) and three lymph node negative (LN−).
Comparison was made with four normal control samples
from age-matched healthy females. QRT-PCR based
miRNA detection panels, which contain 365 cancer related
miRNAs, were interrogated to detect the circulating
miRNA profile in the six cancer specimens and the four
normal controls. The results found three significantly
upregulated circulating miRNAs (miR-20b, miR-106a
and miR-16) and four downregulated circulating miRNAs
www.impactjournals.com/oncotarget
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Figure 4: High efficiency of the plasma-based direct quantification of circulating miRNAs. (A) Details of the procedure
for the RNA-based and plasma-based miRNA analysis for comparison of the two methods. (B–D) Comparison of the RNA-based and
plasma-based analysis for circulating let-7b and miR-92a in three independent samples S1 (B), S2 (C) and S3 (D). E-F: Comparison of the
RNA-based and plasma-based analysis for the different expression of let-7b (E) and miR-92a (F) in plasma samples S4 and S5.
(G) ∆∆Ct value of let-7b and miR-92abetween samples S4 and S5. H-I: The linear correlation with R2 equals 1.0 between the RNA-based and
plasma-based methods for the different expression analysis of let-7b (H) and miR-92a (I) in samples S4 and S5.
www.impactjournals.com/oncotarget
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derived circulating vesicles carrying cell-secreted nucleic
acids and proteins. Exosomes have a smaller diameter
of between 30 and 100 nm. Circulating miRNAs are
protected by protein complexes in forms of microvesicles
or exosomes. Releasing miRNAs from these particles
with high efficiency is essential to quantify circulating
miRNAs. Several methods have been successfully applied
to quantify circulating miRNAs including miRNA array,
miRNA real-time PCR, and high-throughput small RNASEQ. These methods are based on RNA isolation or
small RNA enrichment from serum or plasma. Isolation
of small miRNA molecules is inefficient when using the
regular RNA isolation methods such as RNA purification
columns. Although Trizol reagent is formulated for
mRNA isolation, it is applicable for miRNA extraction.
However, it is unavoidable to have some of the circulating
miRNAs lost due to incomplete protein denaturation and/
or incomplete RNA precipitation because of the high
concentration of proteins serum and plasma. Therefore,
a quantitative analysis of circulating miRNAs with low
abundances becomes inefficient.
The feasibility of quantifying the gene expression
level directly from cell lysates (cell-to-Ct) was primarily
tested and reported in 2013 [25], where multiple reagents
were tested and compared for quantification analysis of

both mRNA and miRNA. Asaga and Hoon reported a
protocol for direct quantifying circulating miRNA from
serum [26] but lacking the accuracy and specificity
examination. Herein we applied a direct quantification
method combining chemical denaturation and heat
denaturation to release circulating miRNAs from both
microvesicles and exosomes followed by a direct
quantitative PCR amplification. We show this method is
more efficient with higher accuracy and specificity for
circulating miRNA analysis, compared with the traditional
purified RNA-based RT-PCR method.
Circulating miRNAs have potential as biomarkers for
cancer diagnosis and prognosis. Developing a convenient
and reliable method with high accuracy and specificity
to measure circulating miRNAs will be of great benefit
to both laboratory screening and clinical applications.
The plasma-based method was successfully applied
herein to breast cancer clinical samples for screening
and validating of circulating miRNAs as biomarkers
for metastatic breast cancer. Changes of miR-106a
levels in breast cancer patients’ blood were correlated with
metastatic status. Although miRNAs in blood as potential
biomarkers for breast cancer has been frequently reported
[23, 24], it is rare for validation of circulating miRNA as a
biomarker for metastatic cancer. In addition to miR-106a,

Figure 5: Identification of circulating miRNAs as novel biomarkers for detecting metastatic breast cancer. (A) Heatmap

of the circulating miRNA profiling analysis using purified RNAs from three lymph node positive (LN+) and three lymph node negative
(LN−), as well as four normal control from age-matched healthy females. Three significantly upregulated circulating miRNAs (miR-20b,
miR-106aand miR-16) and four downregulated circulating miRNAs (miR-671, miR-151-3p, miR-433 and miR-409-3p) in breast cancer
were identified. (B) The method of plasma-based direct quantification of circulating miRNAs was applied to validate the miRNA signature
in A, demonstrating significant upregulation of miR-106a in lymph node positive breast cancer patients compared with normal control.
www.impactjournals.com/oncotarget
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miRNA profiling analysis in plasma of breast
cancer patients and normal control

a subset of circulating miRNAs including miR-20b and
miR-671, were screened and primarily tested as biomarker
candidates for metastatic breast cancer. More clinical
samples are required to further validate the predictive
value of these candidates for metastatic breast cancer
before clinical application.

We customized a human cancer-related miRNA
panel which contains 365 human cancer-related miRNAs
and 5 reference small RNAs, which was prepared by
miRGenes (Shanghai, China). Total RNA was isolated
using Trizol reagent (Life Technologies) from plasma
specimens. The cDNA was prepared as described above.
The miRNA expression profiles in plasma specimens
were performed using the human cancer-related miRNA
panel, based on the quantitative real-time PCR methods.
The result was analyzed by Mev (version 4.9) software.
p < 0.10 was considered significant.

MATERIALS AND METHODS
Plasma collection
Blood samples were collected from breast cancer
patients and age-matched healthy females at the Shanghai
East hospital, Department of Surgery. 5 ml of blood were
collected in EDTA-treated blood-collecting tubes followed
by a centrifugation at speed of 2,000 rpm for 5 min at 4°C.
The supernatant was aliquoted and stored at −80°C. All
the procedures were approved by the Institutional Review
Board (IRB) of Shanghai East Hospital, Tongji University
School of Medicine.

Statistical analysis
Data are presented as mean ± SEM. The standard
two-tailed Student’s t-test was used for statistical analysis,
in which P < 0.05 was considered significant.
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For circulating miRNA analysis, 5 µl of plasma was
mixed with 5 µl of denaturing buffer composed of 2.5%
tween-20, 50 mM Tris and 1 mM EDTA, followed by
heating in a water bath at 75°C for 5 min, then cooling on
ice, and centrifuging at a speed of 12,000 rpm for 10 min
at 4°C. The supernatant was used for miRNA reverse
transcription and real-time PCR.

miRNA QRT-PCR analysis
A M & G miRNA Reverse Transcription kit
(miRGenes, Shanghai, China) was used to prepare the
first strand cDNA of plasma miRNAs following the
manufacturer’s instruction. 5 µl of prepared plasma
solution or 100 ng of purified total RNA from each
plasma specimen was used for miRNA measurement.
After reverse transcription, the cDNA was diluted 1:10100 (for plasma method) or 1:200-1000 (for purified RNA
method) for real-time PCR. The sequences of forward
primers for miR-92a, miR-16, miR-106a, miR-671, let-7b
and 5s rRNA are: miR-92a: attgcacttgtcccggcctg; miR-16:
agcagcacgtaaatattggc; miR-106a: agtgcttacagtgcaggtag;
miR-671: aggaagcccuggagg; let-7b: tgaggtagtaggttgtgtg;
5s rRNA: agtacttggatgggagaccg. The DNA oligoes were
synthesized and purified by GenScript (Nanjing, China). A
universal reverse primer was provided by miRGenes. The
spike-in RNA unisp6 and PCR primers for amplify unisp6
were purchased from Exiqon. 1 µl of unisp6 equals 108
copies. The SYBR Green Master Mix was ABI product
(Applied Biosystem, Life Technologies). The ABI 7900
HT and ABI 7500 Sequence Detection System (Applied
Biosystem, Life Technologies) were used for quantitative
real time PCR assay. 5s rRNA was used for normalization
when necessary.
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